Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Most new drugs are still too costly at launch, ICER says

A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Tuesday 20 October →